Jialiang Wang, Chang Guo, Jiexiao Wang, Xiaopeng Zhang, Jian Qi, Xiang Huang, Zongtao Hu, Hongzhi Wang, Bo Hong
{"title":"肿瘤突变特征揭示EGFR或KRAS突变肺腺癌的危险因素。","authors":"Jialiang Wang, Chang Guo, Jiexiao Wang, Xiaopeng Zhang, Jian Qi, Xiang Huang, Zongtao Hu, Hongzhi Wang, Bo Hong","doi":"10.1177/10732748241307363","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong><i>EGFR</i> and <i>KRAS</i> mutations are frequently detected in lung adenocarcinoma (LUAD). Tumor mutational signature (TMS) determination is an approach to identify somatic mutational patterns associated with pathogenic factors. In this study, through the analysis of TMS, the underlying pathogenic factors of LUAD with <i>EGFR</i> and <i>KRAS</i> mutations were traced.</p><p><strong>Methods: </strong>This was a retrospective study. TMS of LUAD with <i>KRAS</i> and <i>EGFR</i> mutations from the TCGA, OncoSG, and MSK datasets was determined by two bioinformatics tools, namely the \"MutationalPatterns\" and \"FitMS\" packages. Elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) of LUAD clinical specimens was analyzed using capillary electrophoresis.</p><p><strong>Results: </strong>In LUAD with <i>KRAS</i> mutations, TMS analysis indicated that the smoking-related SBS4 signature was enriched. For LUAD with <i>EGFR</i> L858R mutation, the smoking-related SBS4 signature was enriched in the Western population from the TCGA database; however, the smoking-related SBS4 signature was not obvious in Asian LUAD patients. LUAD with <i>EGFR</i> exon19 deletion (19Del) exhibited stronger SBS15 signature, which was related to defective DNA mismatch repair. Capillary electrophoresis analysis showed that an EMAST locus was frequently instable in LUAD with <i>EGFR</i> 19Del. Different from the Western population, Asian LUAD patients with <i>EGFR</i> mutations exhibited the enrichment of SBS1, SBS2, and SBS13 signatures, which were associated with the endogenous mutation process of cytidine deamination.</p><p><strong>Conclusions: </strong>TMS analysis reveals that smoking is associated with LUAD with <i>KRAS</i> mutations. Defective DNA mismatch repair and endogenous cytidine deamination are associated with LUAD with <i>EGFR</i> mutations, especially for the <i>EGFR</i> 19Del. The endogenous mutational process is stronger in Asian LUAD patients than Western LUAD patients.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748241307363"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tumor Mutation Signature Reveals the Risk Factors of Lung Adenocarcinoma with <i>EGFR</i> or <i>KRAS</i> Mutation.\",\"authors\":\"Jialiang Wang, Chang Guo, Jiexiao Wang, Xiaopeng Zhang, Jian Qi, Xiang Huang, Zongtao Hu, Hongzhi Wang, Bo Hong\",\"doi\":\"10.1177/10732748241307363\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong><i>EGFR</i> and <i>KRAS</i> mutations are frequently detected in lung adenocarcinoma (LUAD). Tumor mutational signature (TMS) determination is an approach to identify somatic mutational patterns associated with pathogenic factors. In this study, through the analysis of TMS, the underlying pathogenic factors of LUAD with <i>EGFR</i> and <i>KRAS</i> mutations were traced.</p><p><strong>Methods: </strong>This was a retrospective study. TMS of LUAD with <i>KRAS</i> and <i>EGFR</i> mutations from the TCGA, OncoSG, and MSK datasets was determined by two bioinformatics tools, namely the \\\"MutationalPatterns\\\" and \\\"FitMS\\\" packages. Elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) of LUAD clinical specimens was analyzed using capillary electrophoresis.</p><p><strong>Results: </strong>In LUAD with <i>KRAS</i> mutations, TMS analysis indicated that the smoking-related SBS4 signature was enriched. For LUAD with <i>EGFR</i> L858R mutation, the smoking-related SBS4 signature was enriched in the Western population from the TCGA database; however, the smoking-related SBS4 signature was not obvious in Asian LUAD patients. LUAD with <i>EGFR</i> exon19 deletion (19Del) exhibited stronger SBS15 signature, which was related to defective DNA mismatch repair. Capillary electrophoresis analysis showed that an EMAST locus was frequently instable in LUAD with <i>EGFR</i> 19Del. Different from the Western population, Asian LUAD patients with <i>EGFR</i> mutations exhibited the enrichment of SBS1, SBS2, and SBS13 signatures, which were associated with the endogenous mutation process of cytidine deamination.</p><p><strong>Conclusions: </strong>TMS analysis reveals that smoking is associated with LUAD with <i>KRAS</i> mutations. Defective DNA mismatch repair and endogenous cytidine deamination are associated with LUAD with <i>EGFR</i> mutations, especially for the <i>EGFR</i> 19Del. The endogenous mutational process is stronger in Asian LUAD patients than Western LUAD patients.</p>\",\"PeriodicalId\":49093,\"journal\":{\"name\":\"Cancer Control\",\"volume\":\"32 \",\"pages\":\"10732748241307363\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Control\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10732748241307363\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Control","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10732748241307363","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Tumor Mutation Signature Reveals the Risk Factors of Lung Adenocarcinoma with EGFR or KRAS Mutation.
Introduction: EGFR and KRAS mutations are frequently detected in lung adenocarcinoma (LUAD). Tumor mutational signature (TMS) determination is an approach to identify somatic mutational patterns associated with pathogenic factors. In this study, through the analysis of TMS, the underlying pathogenic factors of LUAD with EGFR and KRAS mutations were traced.
Methods: This was a retrospective study. TMS of LUAD with KRAS and EGFR mutations from the TCGA, OncoSG, and MSK datasets was determined by two bioinformatics tools, namely the "MutationalPatterns" and "FitMS" packages. Elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) of LUAD clinical specimens was analyzed using capillary electrophoresis.
Results: In LUAD with KRAS mutations, TMS analysis indicated that the smoking-related SBS4 signature was enriched. For LUAD with EGFR L858R mutation, the smoking-related SBS4 signature was enriched in the Western population from the TCGA database; however, the smoking-related SBS4 signature was not obvious in Asian LUAD patients. LUAD with EGFR exon19 deletion (19Del) exhibited stronger SBS15 signature, which was related to defective DNA mismatch repair. Capillary electrophoresis analysis showed that an EMAST locus was frequently instable in LUAD with EGFR 19Del. Different from the Western population, Asian LUAD patients with EGFR mutations exhibited the enrichment of SBS1, SBS2, and SBS13 signatures, which were associated with the endogenous mutation process of cytidine deamination.
Conclusions: TMS analysis reveals that smoking is associated with LUAD with KRAS mutations. Defective DNA mismatch repair and endogenous cytidine deamination are associated with LUAD with EGFR mutations, especially for the EGFR 19Del. The endogenous mutational process is stronger in Asian LUAD patients than Western LUAD patients.
期刊介绍:
Cancer Control is a JCR-ranked, peer-reviewed open access journal whose mission is to advance the prevention, detection, diagnosis, treatment, and palliative care of cancer by enabling researchers, doctors, policymakers, and other healthcare professionals to freely share research along the cancer control continuum. Our vision is a world where gold-standard cancer care is the norm, not the exception.